Search Results
Your search for The A matches 31894 pages
Showing 4251 - 4300Preliminary Results From ARROS-1 Phase I Clinical Trial Suggest That NVL-520 May Be Well Tolerated and Active in NSCLC
Preliminary data from a phase I clinical trial of the ROS1 inhibitor NVL-520 to treat patients with non–small cell lung cancer (NSCLC) and other solid tumors suggested that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change and reach cancer cells within...
Small Study of Experimental Drug to Treat Liver Cancer Shows Evidence of Activity With Manageable Side Effects
A new drug designed to inhibit an enzyme that plays a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer and up to three lines of previous unsuccessful treatment, according to a new study published by Reig et al ...
Mosaic Chromosomal Alterations and Risk of Lung Cancer
In a study reported in The Lancet Oncology, Qin et al found that the presence of mosaic chromosomal alterations detected in blood-derived DNA was associated with an increased risk of lung cancer among persons of Chinese and European heritage. Study Details The study involved two cohorts:...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a Chinese phase II trial (CARTIFAN-1) reported in the Journal of Clinical Oncology, Mi et al found that the anti–B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel was active in patients with relapsed or refractory multiple myeloma. Study Details...
Concurrent Olaparib and Radiotherapy for Triple-Negative Breast Cancer
In a French phase I trial reported in JAMA Oncology, Loap et al found that concurrent olaparib and radiotherapy was well tolerated in patients with triple-negative breast cancer who had incomplete pathologic response or unresectable disease after neoadjuvant chemotherapy. Survival outcomes with the ...
Cell-Free DNA Profiling in Patients With Advanced Cancers May Lead to Early Detection of Myeloid Malignancies
Researchers have found that an incidental finding of clonal hematopoiesis in liquid biopsies can be used to trigger hematologic tests to assess the risk of developing myeloid malignancies, according to a new study published by Tagliamento et al in the European Journal of Cancer. The findings were...
Sequential Dosing of Olaparib and Adavosertib in Patients With Advanced Tumors
Olaparib and adavosertib can be safely used to treat patients with cancers that are driven by certain mutations occurring in response to DNA damage if they are given in sequence rather than concurrently, according to a novel study published by Yap et al in the European Journal of Cancer. The...
Researchers Identify Specific Mutations in the BRAF Gene That May Affect Response to Treatment and Survival in Adult Brain Cancers
Researchers have identified a range of genetic mutations in gliomas that may help them understand how different mutations in the BRAF gene interact with other gene mutations—and which ones are more susceptible to targeted treatments in adults—according to a new study published by Schreck et al in...
KEYNOTE-716: Distant Metastasis–Free Survival With Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in The Lancet Oncology by Georgina V. Long, MBBS, PhD, and colleagues, an analysis from the phase III KEYNOTE-716 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival with adjuvant pembrolizumab vs placebo in resected stage IIB or IIC...
Telisotuzumab Vedotin Plus Erlotinib in c-Met Protein–Expressing NSCLC
In a phase Ib trial reported in the Journal of Clinical Oncology, D. Ross Camidge, MD, PhD, and colleagues found that the combination of telisotuzumab vedotin and erlotinib showed activity in c-Met protein–expressing advanced non–small cell lung cancer (NSCLC), including those with an EGFR mutation ...
Biomarker Assessment for Benefit of LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
In a prespecified analysis from the Australian phase II TheraP trial reported in The Lancet Oncology, Buteau et al found that higher gallium-68–labeled PSMA-11 positron-emission tomography (PSMA-PET) mean standardized uptake values (SUVmean) were associated with a greater likelihood of...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Pembrolizumab Plus Chemoradiation Therapy Falls Short in Locally Advanced Head and Neck Cancer
Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to...
Expert Point of View: Jean-Yves Blay, MD, PhD
The invited discussant of the DeFi trial was Jean-Yves Blay, MD, PhD, General Director of the Center Bérard, Lyon, France, and President of Unicancer, the French Federation of Cancer Centers. He called the DeFi study a “rigorous trial” in a “representative population” that “introduces a new class...
DeFi Trial: Novel Gamma Secretase Inhibitor Halts Progression of Desmoid Tumors
Patients with rare desmoid tumors may finally have an effective treatment. A first-in-class gamma secretase inhibitor, nirogacestat, led to an improvement in progression-free survival in the phase III DeFi trial. The results were presented during the Presidential Symposium at the European Society...
Expert Point of View: Alexander M.M. Eggermont, MD; Omid Hamid, MD; and James Larkin, PhD
The results of SWOG S18011 were met with enthusiasm by attendees at the Presidential Symposium of the European Society for Medical Oncology (ESMO) Congress 2022. The ASCO Post captured the thoughts of several melanoma experts, who had somewhat different ideas about the immediate clinical...
SWOG S1801: Addition of Neoadjuvant Pembrolizumab to Adjuvant Pembrolizumab Yields Benefits in High-Risk Resectable Melanoma
In resectable stage III to IV melanoma, three cycles of neoadjuvant pembrolizumab followed by adjuvant pembrolizumab was significantly more beneficial than adjuvant pembrolizumab alone, based on the results of the phase II SWOG S1801 trial presented in a Presidential Symposium at the European...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main take-away is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to ...
Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma: LEAP-002 Fails to Meet Co-primary Endpoints
The highly anticipated final analysis of the phase III LEAP-002 trial failed to meet expectations, as first-line treatment with lenvatinib plus pembrolizumab did not significantly improve outcomes in unresectable advanced hepatocellular carcinoma. Both progression-free survival and overall survival ...
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms
The U.S. Food and Drug Administration (FDA) has approved cobimetinib (Cotellic), an oral inhibitor of MEK1 and MEK2, for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and...
Effect of Invitation to Colonoscopy Screening on Risk of Colorectal Cancer and Risk of Mortality: The NordICC Trial
In a pragmatic trial reported in The New England Journal of Medicine, Bretthauer et al, on behalf of the Nordic-European Initiative on Colorectal Cancer (NordICC) Study Group, found a reduced risk of colorectal cancer diagnosis but no significant reduction in disease-specific mortality among...
Expert Point of View: James Larkin, PhD and Andrea Cercek, MD
Invited discussant James Larkin, PhD, a clinical researcher at the Royal Marsden Hospital, London, commented on the findings from NICHE-2.1 “These striking data are consistent with the recent report in locally advanced mismatch repair–deficient [dMMR] rectal cancer from Memorial Sloan Kettering.2...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Expert Point of View: Bernard Escudier, MD and Brian I. Rini, MD
To put the CheckMate 914, IMmotion010, and PROSPER trials into context, The ASCO Post spoke with Bernard Escudier, MD, former Chair of the Genitourinary Group of the Institut Gustave Roussy, Villejuif, France. In general, Dr. Escudier believes that studies to date are not robust enough to justify...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
Managing Primary Prophylactic Colony-Stimulating Factor Use in Patients Receiving Regimens Associated With Intermediate Risk for Febrile Neutropenia
In a study reported in the Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, FASCO, and colleagues found that a standing order entry (SOE) for vs an alert against use of primary prophylactic colony-stimulating factor (PP-CSF) for patients receiving first-line regimens for cancer associated...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Expert Point of View: Mary O’Brien, MD
Formal discussant Mary O’Brien, MD, Head of the Lung Unit, the Royal Marsden Hospital, NHS Foundation Trust, London, commented on the POSEIDON trial. “The POSEIDON trial is the largest data set we have on KRAS-mutated [non–small cell lung cancer], with a positive signal in picking up some patients...
Focal Adhesion Kinase Inhibitor in Patients With Meningioma and Somatic NF2 Mutations
As reported in the Journal of Clinical Oncology by Priscilla K. Brastianos, MD, PhD, and colleagues, the phase II Alliance A071401 trial showed activity of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with recurrent or progressive grade 1 to 3 meningioma and somatic NF2...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
Expert Point of View: Natasha Leighl, MD
“Platinum-ineligible patients are typically excluded from clinical trials, yet they represent the majority of patients that we diagnose and treat—patients with poor performance status and comorbidities,” said invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto....
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?
The KRAS G12C inhibitor sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of disease progression or death by 34% compared with standard second-line docetaxel for patients with previously treated non–small cell lung cancer (NSCLC) and KRAS G12C mutations....
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Expert Point of View: Sanjay Popat, FRCP, PhD
“Adjuvant osimertinib has been adopted widespread as a standard of care as a result of the primary results of ADAURA,” said formal discussant Sanjay Popat, FRCP, PhD, medical oncologist and lung specialist at the Royal Marsden Hospital, NHS Foundation Trust, London. “We have more granularity about ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Andrea McKee, MD, and Brady McKee, MD, Honored With the James L. Mulshine, MD, National Leadership Award for Ensuring Equitable Access to High-Quality Lung Cancer Screenings
Andrea McKee, MD, and the late Brady McKee, MD, will be honored with the James L. Mulshine, MD, National Leadership Award on Thursday, November 3, at the Prevent Cancer Foundation’s 19th annual Quantitative Imaging Workshop. The annual Mulshine Award is given to an individual or individuals who has ...
Highlights From the ESMO Congress 2022
At this year’s European Society for Medical Oncology (ESMO) Congress, we experienced an eagerly awaited return to normality (or almost), and the quality of the science on display was anything but disappointing: from molecular medicine to treatment de-escalation, from early cancer detection and...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
PSA Screening Rates and Incidence of Metastatic Prostate Cancer at VHA Facilities
In a retrospective cohort study reported in JAMA Oncology, Bryant et al found that prostate-specific antigen (PSA) screening rates at Veterans Health Administration (VHA) facilities declined between 2005 and 2019—and that diagnoses of metastatic prostate cancer increased over the same time period....
Addition of Capecitabine to Temozolomide in Advanced Pancreatic Neuroendocrine Tumors
As reported in the Journal of Clinical Oncology by Pamela L. Kunz, MD, and colleagues, the phase II ECOG-ACRIN E2211 trial has shown significantly prolonged progression-free survival with the addition of capecitabine to temozolomide in patients with advanced pancreatic neuroendocrine tumors. Study ...
Genomic Microsatellite Signature Assay to Identify Germline MMRD in Patients With CMMRD
In an analysis reported in the Journal of Clinical Oncology, Chung et al described the performance of a newly developed assay using genomic microsatellite signatures (LOGIC; low-pass genomic instability characterization) in detecting germline mismatch repair deficiency (MMRD) in patients with the...
Increased Mortality From Comorbid Cancer and Cardiovascular Disease Associated With Increased Social Vulnerability
In a U.S.-based cross-sectional study reported in JACC: CardioOncology, Sarju Ganatra, MD, of Lahey Hospital & Medical Center, Burlington, Massachusetts, and colleagues found that mortality from comorbid cancer and cardiovascular disease (CVD) was significantly higher in counties with higher...
Chemotherapy Outcomes in Noninfant Childhood ALL With 11q23/KMT2A Rearrangements
In a retrospective study reported in the Journal of Clinical Oncology, Attarbaschi et al described outcomes in patients with noninfant childhood acute lymphoblastic leukemia (ALL) and 11q23/KMT2A rearrangements treated with chemotherapy regimens between 1995 and 2010. Study Details The study...
Treatment of AJCC Stage IV Intrahepatic Cholangiocarcinoma
This is Part 4 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss the treatment of AJCC stage IV intrahepatic cholangiocarcinoma. The...
Adjuvant Therapy in Biliary Tract Cancer
This is Part 3 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss the role of adjuvant therapy in biliary tract cancer. The patient is a ...
Second-Line Therapy and Beyond in Hepatocellular Carcinoma
This is Part 2 of Updates in Hepatobiliary Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Ghassan Abou-Alfa, Richard Finn, and Rachna Shroff discuss second-line therapy and beyond in hepatocellular carcinoma. The...
